Your browser doesn't support javascript.
loading
Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma.
Ichimiya, Shu; Fujimura, Akiko; Masuda, Muneyuki; Masuda, Shogo; Yasumatsu, Ryuji; Umebayashi, Masayo; Tanaka, Hiroto; Koya, Norihiro; Nakagawa, Shinichiro; Yew, Poh Yin; Yoshimura, Sachiko; Onishi, Hideya; Nakamura, Masafumi; Nakamura, Yusuke; Morisaki, Takashi.
Afiliación
  • Ichimiya S; Department of Cancer Therapy and Research, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Fujimura A; Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Masuda M; Department of Cancer Therapy and Research, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Masuda S; Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Yasumatsu R; Department of Head and Neck Surgery, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Umebayashi M; Department of Cancer Therapy and Research, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Tanaka H; Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Koya N; Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Nakagawa S; Department of Cancer Immunotherapy, Fukuoka General Cancer Clinic, Fukuoka, Japan.
  • Yew PY; Department of Cancer Immunotherapy, Fukuoka General Cancer Clinic, Fukuoka, Japan.
  • Yoshimura S; Department of Cancer Immunotherapy, Fukuoka General Cancer Clinic, Fukuoka, Japan.
  • Onishi H; Department of Cancer Immunotherapy, Fukuoka General Cancer Clinic, Fukuoka, Japan.
  • Nakamura M; R&D Department, Cancer Precision Medicine Inc, Kanagawa, Japan.
  • Nakamura Y; R&D Department, Cancer Precision Medicine Inc, Kanagawa, Japan.
  • Morisaki T; Department of Cancer Therapy and Research, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Immunol Invest ; 51(5): 1498-1514, 2022 Jul.
Article en En | MEDLINE | ID: mdl-34486463
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma / Vacunas contra el Cáncer / Carcinoma Ductal Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Immunol Invest Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma / Vacunas contra el Cáncer / Carcinoma Ductal Tipo de estudio: Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Immunol Invest Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido